IL114932A0 - Excitatory amino acid receptor antagonists - Google Patents

Excitatory amino acid receptor antagonists

Info

Publication number
IL114932A0
IL114932A0 IL11493295A IL11493295A IL114932A0 IL 114932 A0 IL114932 A0 IL 114932A0 IL 11493295 A IL11493295 A IL 11493295A IL 11493295 A IL11493295 A IL 11493295A IL 114932 A0 IL114932 A0 IL 114932A0
Authority
IL
Israel
Prior art keywords
amino acid
receptor antagonists
acid receptor
excitatory amino
excitatory
Prior art date
Application number
IL11493295A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/500,303 external-priority patent/US5717109A/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL114932A0 publication Critical patent/IL114932A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/08—Saturated compounds containing ether groups, groups, groups, or groups
    • C07C62/12—Saturated compounds containing ether groups, groups, groups, or groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/18—Saturated compounds containing keto groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/18—Saturated compounds containing keto groups
    • C07C62/22—Saturated compounds containing keto groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/18—Saturated compounds containing keto groups
    • C07C62/26—Saturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL11493295A 1994-09-08 1995-08-14 Excitatory amino acid receptor antagonists IL114932A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30325594A 1994-09-08 1994-09-08
US08/500,303 US5717109A (en) 1994-09-08 1995-07-10 Excitatory amino acid receptor antagonists

Publications (1)

Publication Number Publication Date
IL114932A0 true IL114932A0 (en) 1995-12-31

Family

ID=26973356

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11493295A IL114932A0 (en) 1994-09-08 1995-08-14 Excitatory amino acid receptor antagonists

Country Status (9)

Country Link
EP (1) EP0771196B1 (de)
JP (1) JPH10505597A (de)
AU (1) AU701863B2 (de)
CA (1) CA2199508A1 (de)
DE (1) DE69513832T2 (de)
ES (1) ES2139928T3 (de)
IL (1) IL114932A0 (de)
NZ (1) NZ291597A (de)
WO (1) WO1996007405A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912248A (en) * 1995-11-16 1999-06-15 Eli Lilly And Company Excitatory amino acid receptor antagonists
ZA969485B (en) * 1995-11-16 1998-05-12 Lilly Co Eli Excitatory amino acid receptor antagonists.
US5688826A (en) * 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
GB9621789D0 (en) * 1996-10-18 1996-12-11 Lilly Industries Ltd Pharmaceutical compounds
ES2131463B1 (es) * 1997-04-08 2000-03-01 Lilly Sa Derivados de ciclopropilglicina con propiedades farmaceuticas.
DE19801648A1 (de) * 1998-01-17 1999-07-22 Bayer Ag alpha-Substituierte Lactone
DE19801646A1 (de) * 1998-01-17 1999-07-22 Bayer Ag Substituierte alpha,beta-annellierte Butyrolactone
DE19801647A1 (de) 1998-01-17 1999-07-22 Bayer Ag Substituierte beta,gamma-annellierte Lactone
DE19801636A1 (de) 1998-01-17 1999-07-22 Bayer Ag Substituierte bicyclische Lactone
EA201791289A1 (ru) 2014-12-11 2017-12-29 Президент Энд Феллоуз Оф Гарвард Колледж Ингибиторы клеточного некроза и связанные с ними способы

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1305177C (en) * 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
DE3740840A1 (de) * 1987-11-27 1989-06-08 Schering Ag 2,2-difluorcyclopropylethanderivate, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
US5177109A (en) * 1988-05-16 1993-01-05 G. D. Searle & Co. 2-amino-4,5-methyleneadipic acid compounds for treatment of CNS disorders
JP2757960B2 (ja) * 1988-10-17 1998-05-25 サントリー株式会社 （２Ｒ，３Ｓ，４Ｓ）−α−（カルボキシシクロプロピル）グリシン
GB9325368D0 (en) * 1993-12-10 1994-02-16 Univ Bristol Organic compounds

Also Published As

Publication number Publication date
EP0771196A1 (de) 1997-05-07
DE69513832D1 (de) 2000-01-13
AU701863B2 (en) 1999-02-04
EP0771196B1 (de) 1999-12-08
EP0771196A4 (de) 1997-09-03
JPH10505597A (ja) 1998-06-02
AU3278195A (en) 1996-03-27
NZ291597A (en) 1998-12-23
CA2199508A1 (en) 1996-03-14
WO1996007405A1 (en) 1996-03-14
DE69513832T2 (de) 2000-04-13
ES2139928T3 (es) 2000-02-16

Similar Documents

Publication Publication Date Title
IL111789A0 (en) Excitatory amino acid receptor antagonists
ZA969485B (en) Excitatory amino acid receptor antagonists.
GR3035156T3 (en) Excitatory amino acid receptor modulators
HU9603525D0 (en) Vironectin receptor antagonists
HU9601529D0 (en) Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists
HU9503402D0 (en) Neurokinin receptor antagonists
HK1029574A1 (en) 1-amino-alkylcyclohexane nmda receptor antagonists
IL94777A0 (en) Tetrazole excitatory amino acid receptor antagonists
GB9605429D0 (en) Excitatory amino acid receptor antagonists
HU9601176D0 (en) Adhesion-receptor antagonists
NZ323205A (en) Excitatory amino acid derivatives
IL114932A0 (en) Excitatory amino acid receptor antagonists
EP1080182A4 (de) Polypeptide mit modifizierten aminosäuren
ZA959434B (en) Adhesion receptor antagonists
ZA956812B (en) Excitatory amino acid receptor antagonists.
AU7731096A (en) Excitatory amino acid receptor antagonists
ZA98256B (en) Tachykinin antagonists
EP0688319A4 (de) 4-hydroxy-3-nitro-1,2-dihydrochinolin-2-one und deren verwendung als excitatorische aminosäuren und glycin rezeptor antagonisten
ZA961159B (en) Adhesion receptor antagonists
IL114046A0 (en) New opioid peptide antagonists
AU5349894A (en) 2,5-dihydro-2,5-dioxo-1(H)-azepines and 2,5-dihydro-2-oxo-1(H)-azepines and the use thereof as excitatory amino acid and glycine receptor antagonists
GB9605430D0 (en) Excitatory amino acid receptor antagonists
AU6172696A (en) 4,5-bridged quinoxalinediones and quinolones and the use thereof as excitatory amino acid receptor antagonists
GB9605434D0 (en) Excitatory amino acid derivatives
ZA954311B (en) New oploid peptide antagonists